Monitor the ASH 2026 presentation in December for full ronde-cel data and any updates on PiNACLE enrollment completion expected by year-end. The BLA submission in H2 2027 is the next major catalyst; the $80M private placement reduces near-term dilution risk but the $194M cash balance plus proceeds still only funds into 2028, so additional financing may be needed before commercialization.
Price Chart
Executive Summary
Lyell Immunopharma reported Q3 2026 results with a GAAP net loss of $45.5M, wider than the $38.8M loss in Q3 2025, driven by a $12.7M increase in R&D expenses from higher clinical trial activity. The company highlighted strong ronde-cel clinical data (91% ORR, 77% CR in 3L+ LBCL) accepted for ASH 2026, completed an $80M private placement extending cash runway into 2028, and reiterated its BLA submission timeline for ronde-cel in the second half of 2027.
Key Financial Metrics
Key Facts
- Q3 2026 GAAP net loss of $45.5M vs $38.8M in Q3 2025, a $6.7M increase
- R&D expenses rose to $40.9M from $28.2M, up $12.7M due to increased clinical trial activity
- Cash, cash equivalents and marketable securities at $194.0M as of Sep 30, 2026, down from $247.2M at Dec 31, 2025
- Announced $80.0M private placement in November 2026, extending cash runway into 2028
- Updated ronde-cel data: 91% ORR, 77% CR in 44 efficacy-evaluable 3L+ LBCL patients; median DOR and PFS not reached
- PiNACLE pivotal data expected mid-2027, BLA submission in second half of 2027
- Completed technology transfer of LYL273 to LyFE Manufacturing Center; End-of-Phase 1 FDA meeting expected in 2027
- Revenue was $3K for Q3 2026, essentially unchanged from $15K in Q3 2025
Financial Impact
Net loss increased by $6.7M YoY to $45.5M; cash burn of $53.2M in 9M 2026 (from $194.0M to $247.2M plus $80M placement); $80M private placement added to balance sheet post-quarter
Risk Factors
- Pre-revenue biotech with no approved products; net loss widening on higher clinical spend
- Cash runway extended into 2028 but still dependent on successful clinical and regulatory milestones
- Ronde-cel BLA submission in H2 2027 is subject to clinical data and FDA review risks
- LYL273 is in early-stage Phase 1/2 with no near-term catalyst for value inflection
- Private placement at undisclosed price may cause dilution; terms not disclosed in filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-070161 |
| Document: lyel-20261104.htm | 0001628280-26-070161 |
| Document: 0001628280-26-070161-index-headers.html | 0001628280-26-070161 |
| Document: 0001628280-26-070161-index.html | 0001628280-26-070161 |
| Document: 0001628280-26-070161.txt | 0001628280-26-070161 |
| 8-K Data (Synthetic) | 0001628280-26-070161 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Nov 5, 2026 today | Insider Cluster | $15.40 | awaiting T+1 | awaiting T+1 | $15.00 (−2.60%) |
Nov 5, 2026 today | Insider Buy | $15.40 | awaiting T+1 | awaiting T+1 | $15.00 (−2.60%) |
Nov 4, 2026 1d ago | 8-K | No price | awaiting T+1 | awaiting T+1 | No price |
Nov 4, 2026 1d ago | Press Release | $15.08 | awaiting T+1 | awaiting T+1 | $15.00 (−0.53%) |
Nov 4, 2026 1d ago | 8-K | $15.43 $15.00 | ▲ +2.79% | ▼ −1.62% | $15.00 (+2.79%) |
Nov 4, 2026 1d ago | Press Release | $15.43 $15.00 | ▼ −2.79% | ▲ +1.62% | $15.00 (−2.79%) |
Aug 25, 2026 10w ago | Insider Cluster | $14.80 $14.61 | ▼ −1.28% | ▼ −1.94% | $15.00 (+1.35%) |
Jul 22, 2026 15w ago | EFFECT | $12.84 $12.78 | ▼ −0.47% | ▲ +0.77% | $15.00 (+16.82%) |
Jun 15, 2026 20w ago | Insider Cluster | $12.44 $12.52 | ▲ +0.64% | ▲ +1.89% | $15.00 (+20.58%) |
Jun 12, 2026 20w ago | Press Release | $13.50 $13.55 | ▲ +0.37% | ▼ −1.39% | $15.00 (+11.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers